ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 893

Nuclear Factor-κB Activation by Type II Collagen Peptide in Osteoarthritic Chondrocytes: Its Inhibition by Hyaluronan Via CD44

Tadashi Yasuda, Dept of Sports Medicine, Tenri University, Tenri, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chondrocytes, hyaluronate, matrix metalloproteinase (MMP), signal transduction and type II collagen

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Some proteolytic products of cartilage matrix may contribute to cartilage destruction through their catabolic activities. Recently, we have found that a 24-mer synthetic peptide of type II collagen named CB12-II stimulates type II collagen cleavage with induction of matrix metalloproteinase (MMP)-13 in cartilage explant culture. Although the intracellular signaling that leads to cartilage destruction is mediated by a cluster of catabolic pathways including nuclear factor-κB (NF-κB), the effect of CB12-II on NF-κB remains unclear.

Hyaluronan (HA) of high molecular weight is widely used in the treatment of osteoarthritis (OA) by intra-articular injection. An increasing body of evidence indicates that HA suppresses catabolic actions by proinflammatory cytokines like interleukin-1 and matrikines such as fibronectin fragments. However, little is known of HA effect on actions of CB12-II through interaction with HA receptor such as CD44.

This study was aimed to examine activation of NF-κB in association with MMP-13 production by CB12-II and its inhibition by HA in chondrocytes.

Methods:

Cartilage explants harvested from OA knee joints or isolated chondrocytes in monolayer were incubated with CB12-II or its scramble peptide with or without pretreatment with 2700 kDa HA. In another set of experiments, following preincubation with anti-CD44 antibody or non-specific IgG, cartilage explants were incubated with or without HA, followed by coincubation with CB12-II or the scramble peptide.

Enzyme-linked immunosorbent assays for phosphorylated p65 NF-κB and MMP13 were performed using total cell lysates and culture supernatants, respectively.

Results:

When cartilage explants or chondrocytes in monolayer were incubated with CB12-II, the type II collagen peptide activated NF-κB in association with enhanced MMP-13 production. Inhibition studies with the specific inhibitor indicated the requirement of NF-κB for CB12-II-induced MMP-13 production. Pretreatment with HA resulted in significant suppression of CB12-II-stimulated MMP-13 production in cartilage as well as in chondrocyte monolayer cultures. HA suppressed NF-κB activation by CB12-II, leading to a decrease in MMP-13 production. Anti-CD44 antibody reversed HA effect on CB12-II action.

Conclusion:

The present study clearly demonstrated that HA suppressed CB12-II-activated NF-κB via CD44 in OA articular chondrocytes, leading to decreased MMP-13 production. HA could down-regulate the catabolic action of type II collagen fragments in osteoarthritic joints through the mechanism demonstrated in this study.


Disclosure:

T. Yasuda,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nuclear-factor-%ce%bab-activation-by-type-ii-collagen-peptide-in-osteoarthritic-chondrocytes-its-inhibition-by-hyaluronan-via-cd44/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology